NZ 597259 Disclosed is a bispecific antibody comprising: a first antigen combining site that binds to C5a and a second antigen combining site that binds to C5b, wherein the bispecific antibody bound to C5a inhibits the interaction between C5a and the C5a receptor and wherein the bispecific antibody bound to C5b inhibits the assembly or lytic activity of the terminal complement complex (TCC). Also disclosed is the use of the bispecific antibody in the manufacture of a medicament for treating a patient afflicted with a complement-associated disorder.